Orally active benzoxazole derivative as 5-HT3 receptor partial agonist for treatment of diarrhea-predominant irritable bowel syndrome

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 7075-7079

  Yoshida, Satoshi ^a   Shiokawa, Sojiro ^a   Kawano, Ken Ichi ^a   Ito, Tomoko ^a   Murakami, Hiroshi ^a   Suzuki, Hisashi ^a   Sato, Yasuo ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 7 METHYL 2 (1 HOMOPIPERAZINYL)BENZOXAZOLE; ANTIDIARRHEAL AGENT; BENZOXAZOLE DERIVATIVE; CYTOCHROME P450 2D6; GLUCOSE 6 PHOSPHATE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MAGNESIUM CHLORIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SEROTONIN; SEROTONIN 3 AGONIST; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG METABOLISM; DRUG STABILITY; DRUG SYNTHESIS; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ILEUM CONTRACTION; IN VITRO STUDY; IN VIVO STUDY; IRRITABLE COLON; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; RAT;

ADMINISTRATION, ORAL; ANIMALS; BENZOXAZOLES; CEREBRAL CORTEX; COLON; DIARRHEA; GASTROINTESTINAL TRANSIT; GUINEA PIGS; ILEUM; IRRITABLE BOWEL SYNDROME; MALE; MICE; MICROSOMES, LIVER; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN, 5-HT3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27444446821     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050209t     Document Type: Article

References (30)

1. 3 receptors. Med. Res. Rev. 1990, 10, 441-475 and references therein.
2. Gerhardt, C. C.; Heerkhuizen, H. Functional characteristics of heterogously expressed 5-HT receptors. Eur. J. Pharmacol. 1997, 334, 1-23.
3. Boess, F. G.; Martin, I. L. Molecular biology of 5-HT receptors. Neuropharmacology 1994, 33, 275-317.
4. 3 receptors: Pharmacologic and therapeutic aspects. J. Clin. Pharmacol. 1995, 35, 845-855.
5. Hoyer, D.; Clarke, D. E.; Fozard, J. R. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 1994, 46, 157-203.
6. 3 receptor antagonists. Exp. Opin. Ther. Pat. 1994, 4, 669-680.
7. 3 receptor antagonists: An overview of their present status and future potential in cancer therapy-induced emesis. Drugs 1991, 42, 551-568.
8. Sanger, G. J.; Nelson, D. R. Selective and functional 5-hydroxytryptamines receptor antagonism by BRL43694(granisetron). Eur. J. Pharmacol. 1989, 159, 113-124.
9. 3 receptors. Br. J. Pharmacol. 1988, 94, 397-412.
10. Camilleri, M.; Northcutt A. R.; Kong, S.; Dukes, G. E.; McSorley, D.; and Mangel. A. W. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet. 2000, 355, 1035-1040.
11. Camilleri, M. Safety concerns about alosetron. Arch. Intern. Med. 2002, 162, 100-101.
12. Beck, I. T. Possible mechanisms for ischemic colitis during alosetron therapy. Gastroenterology 2001, 121, 231-232.
13. Friedel, D.; Thomas, R.; Fisher, R. S. Ischemic colitis during treatment with alosetron. Gastroenterology 2001, 120, 557-560.
14. Steadman, C. J.; Talley, N. J.; Phillips, S. F.; Zinsmeister, A. R. Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: A Plot Study. Mayo Can. Proc. 1992, 67, 732-738.
15. Talley, N. J. 5-Hydroxytryptamine agonists and antagonists in the modulation of gastrointestinal motility and sensation: clinical implications. Aliment. Pharmacol. Ther. 1992, 6, 273-289.
16. 3 receptor partial agonists in the gut. J. Med. Chem. 1998, 41, 3015-3021.
17. 3 receptor ligand: agonistic activities on gastroenteric motility. Biol. Pharm. Bull. 1997, 20, 752-755.
18. Marcel, J. de Groot; Mark, J. Ackland; Valerie, A. Horne; Alexander A. Alex and Barry C. Jones CYP2D6 catalyzed N-dealkylation reactions. J. Med. Chem. 1999, 42, 4062-4070.
19. Dunner, J. Ueber das produkt der einwirkung von schwefelkohleustoff auf das orthoamidophenol. Ber. 1876, 9, 465-466.
20. 3 receptor agonist action in the gut. Chem. Pharm. Bull. 1998, 46, 445-451.
21. Kawano, K.; Mori, T.; Yoshida, S. Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function. Neurogastroenterol Motil. 2005, 17, 290-301.
22. 3 receptors in rat brain using radioligand binding. Nature 1987, 330, 746-748.
23. 3 ligand in the case of its binding to the receptor.
24. Mie, K.; Hisashi, S.; Izumi, K. Studies on the cytochrome P450-mediated metabolic properties of miocamycin. Drug Metab. Dispos. 2000, 28, 409-417.
25. For detailed binding profile of 6g, see ref 21.
26. 4 receptor dual antagonist, on colonic function in vivo. J. Pharmacol. Exp. Ther. 1993, 266, 74-80.
27. 2-adrenoreceptor agonists upon colonic propulsion. Drug Dev. Res. 1986, 9, 241-247.
28. Cross, G. G.; Fisher, A.; Henderson, G. N.; Smyth, T. A. Ipsomigration. XXIV. Nitration of 2-methylphenols. Formation and rearrangement of 6-methyl-6-mitrocyclohexa-2,4-dienones. Can J. Chem. 1984, 62, 1446-1451.
29. Clewley, R. G.; Cross, G. G.; Fischer, A.; Henderson, G. N. Formation of 4-halo-4-nitrocyclohexa-2,5-dienones on nitration of p-halophenols and p-halophenyl acetates. Tetrahedron 1989, 5, 1299-1310.
30. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.